Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma
Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma
Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera
Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL
COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state
MRD validated as a surrogate endpoint for survival in AML
Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome
IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis
Exploring genomic insights in acute lymphoblastic leukaemia treatment
AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Essential breast cancer medicines
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types